Literature DB >> 22664916

MicroRNAs in diabetes and diabetes-associated complications.

Johan Lorenzen1, Regalla Kumarswamy, Seema Dangwal, Thomas Thum.   

Abstract

Diabetes mellitus due to its high prevalence and associated complications is a major socioeconomic health problem. Diabetes is characterized by multiple macro- and microvascular complications (e.g. diabetic nephropathy, cardiomyopathy, neuropathy, retinopathy). Research efforts aim to elucidate pathophysiological mechanisms contributing to the disease process. MicroRNAs are endogenous small single stranded molecules regulating targets through mRNA cleavage or translational inhibition. MicroRNAs regulate many biological cellular functions and are often deregulated during diseases. The aim of the present article is to summarize the current knowledge of the impact of microRNAs on the development of diabetes and its associated complications including endothelial and vascular smooth muscle cell dysfunction, diabetic cardiomyopathy, diabetic nephropathy, regulation of pancreatic beta cell function as well as skeletal muscle and hepatic involvement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664916     DOI: 10.4161/rna.20162

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  31 in total

1.  miR-146a mediates thymosin β4 induced neurovascular remodeling of diabetic peripheral neuropathy in type-II diabetic mice.

Authors:  Lei Wang; Michael Chopp; XueRong Lu; Alexandra Szalad; LongFei Jia; Xian Shuang Liu; Kuan-Han Wu; Mei Lu; Zheng Gang Zhang
Journal:  Brain Res       Date:  2018-11-27       Impact factor: 3.252

2.  Developmental exposure to valproic acid alters the expression of microRNAs involved in neurodevelopment in zebrafish.

Authors:  Neelakanteswar Aluru; Kristina L Deak; Matthew J Jenny; Mark E Hahn
Journal:  Neurotoxicol Teratol       Date:  2013-10-12       Impact factor: 3.763

Review 3.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

4.  Exosomes Derived From Schwann Cells Ameliorate Peripheral Neuropathy in Type 2 Diabetic Mice.

Authors:  Lei Wang; Michael Chopp; Alexandra Szalad; XueRong Lu; Yi Zhang; Xinli Wang; Pasquale Cepparulo; Mei Lu; Chao Li; Zheng Gang Zhang
Journal:  Diabetes       Date:  2020-01-08       Impact factor: 9.461

5.  miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway.

Authors:  Shuzhi Zhao; Tao Li; Jun Li; Qianyi Lu; Changjing Han; Na Wang; Qinghua Qiu; Hui Cao; Xun Xu; Haibing Chen; Zhi Zheng
Journal:  Diabetologia       Date:  2015-12-19       Impact factor: 10.122

6.  Connective tissue growth factor (CCN2) and microRNA-21 are components of a positive feedback loop in pancreatic stellate cells (PSC) during chronic pancreatitis and are exported in PSC-derived exosomes.

Authors:  Alyssa Charrier; Ruju Chen; Li Chen; Sherri Kemper; Takako Hattori; Masaharu Takigawa; David R Brigstock
Journal:  J Cell Commun Signal       Date:  2014-01-26       Impact factor: 5.782

Review 7.  MicroRNA in myogenesis and muscle atrophy.

Authors:  Xiaonan H Wang
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-05       Impact factor: 4.294

8.  miR-195 regulates SIRT1-mediated changes in diabetic retinopathy.

Authors:  Rokhsana Mortuza; Biao Feng; Subrata Chakrabarti
Journal:  Diabetologia       Date:  2014-02-26       Impact factor: 10.122

9.  Myotube-derived exosomal miRNAs downregulate Sirtuin1 in myoblasts during muscle cell differentiation.

Authors:  Alexis Forterre; Audrey Jalabert; Karim Chikh; Sandra Pesenti; Vanessa Euthine; Aurélie Granjon; Elizabeth Errazuriz; Etienne Lefai; Hubert Vidal; Sophie Rome
Journal:  Cell Cycle       Date:  2013-10-23       Impact factor: 4.534

Review 10.  MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.

Authors:  Anita Thyagarajan; Ahmed Shaban; Ravi Prakash Sahu
Journal:  J Pharmacol Exp Ther       Date:  2017-10-20       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.